ICON to Acquire Aptiv Solutions
31 Março 2014 - 7:00AM
Business Wire
Acquisition enhances ICON’s capabilities in
adaptive and medical device trials and in Japan
ICON plc, (NASDAQ:ICLR), a global provider of
outsourced development services to the pharmaceutical,
biotechnology and medical device industries, today announced that
it has agreed, subject to certain closing conditions, to acquire
Aptiv Solutions for a cash consideration of $143.5 million.
Aptiv Solutions is owned by The Halifax Group, SV Life Sciences,
Comvest Partners and Management.
Headquartered in Reston Virginia, and with operations in 16
countries, Aptiv Solutions is a recognised leader in the design and
execution of adaptive clinical trials for pharmaceutical and
biotech customers. The company’s ADDPLAN® software supports the
design, simulation and analysis of adaptive trials and is used by
FDA, EMA and Japan’s PMDA, as well as over fifty top pharmaceutical
and medical device companies and academic researchers.
Aptiv Solutions also owns Niphix, a full-service,
oncology-focused CRO serving both Japanese and international
customers and this will be combined with ICON’s current operations
in Tokyo and Osaka. In addition, Aptiv Solutions has extensive
experience in the management of medical device trials, leveraging
its adaptive capabilities and regulatory expertise to expedite the
development of a wide range of medical devices.
Commenting on the acquisition, Dr. Nuala Murphy, President, ICON
Clinical Research Services, said: “ICON’s market-leading innovation
is helping our customers to reduce the time and cost of drug
development. We are achieving this through the combination of our
industry expertise and enabling technologies such as ICONIK and
Firecrest. Aptiv Solutions’ adaptive trial capabilities will
further differentiate and enhance our services to help our
customers identify the most promising drug candidates earlier.
Their presence in Japan will also broaden our existing capabilities
in this market.”
“ICON is the perfect fit for Aptiv Solutions” said Pat Donnelly,
Chairman and Chief Executive of Aptiv Solutions. “Our unique
technology and expertise in integrated design and execution of
adaptive trials, our strength in medical device development and our
strong position in oncology in Japan are key areas of
differentiation. ICON’s excellence in execution, geographic reach,
and shared focus on innovation will position the combined entity as
the go-to service provider for design and execution of adaptive
trials for drug, diagnostic and medical device companies in a fast
growing market.”
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
About ICON plc
ICON plc is a global provider of outsourced development services
to the pharmaceutical, biotechnology and medical device industries.
The company specialises in the strategic development, management
and analysis of programs that support clinical development - from
compound selection to Phase I-IV clinical studies. ICON currently
has approximately 10,300 employees, operating from 77 locations in
38 countries.
Further information is available at www.iconplc.com.
About Aptiv Solutions
Aptiv Solutions is a global development services company focused
on enhancing clinical trial decision-making, efficiency and
productivity for pharmaceutical, biotech and medical device
sponsors. It is the only CRO to offer design, simulation and
execution of adaptive clinical trials and a novel statistical
sampling approach to risk-based monitoring. These services span the
entire product development cycle from first in human through
regulatory approval to post-marketing. Aptiv Solutions has more
than 850 professionals in North America, Eastern and Western
Europe, Israel and Japan.
Further information is available at
www.aptivsolutions.com.
ICON/ICLR-F
ICONBrendan Brennan, + 353-1-291-2000Chief Financial
OfficerorSimon Holmes, + 353-1-291-2000EVP Investor Relations &
Corporate DevelopmentorAptiv SolutionsPhillip Birch, +44
1628 643925SVP Global Strategic Marketing
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024